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httpcense.Abstract Setting: Most of the observational studies suggested that pulmonary hypertension
occurs in as low as 5% to as high as 21 % of patients infected with schistosomiasis. There were
no reports of the real incidence in our locality.
Objective: To evaluate the presence of pulmonary hypertension in Bilharzial patients.
Materials and methods: A case control study was done; ﬁfty bilharzial patients fulﬁlled inclusion
criteria and were matched with forty control subject. All patients and control were subjected to full
clinical assessment. Patient group was subdivided according to abdominal sonography into ﬁne and
thick hepatic peri-portal ﬁbrosis (PPF). Complete Liver function tests and Echocardiography were
done for all patients.
Results: The mean age was 34.24 + 9.68 and 33.9 + 9.23 years for patients and control groups.
Patients with thick PPF showed a signiﬁcant decrease in prothrombin concentration (P
value = 0.000) and increase in total bilirubin than those with ﬁne PPF (P value = 0.014). Eight Bil-
harzial patients had PASP >30 mmHg (range 30–38 mmHg) representing 16% of this group. There
was a statistically signiﬁcant decrease in ejection fraction (EF) (P value = 0.016) and increase in
pulmonary artery pressure (P value = 0.001) in patients versus control. Patients with thick PPF
showed a signiﬁcant decrease in the values of ejection fraction (P value 0.02) and increase in the
values of pulmonary artery pressure (P value = 0.001) compared with those with ﬁne PPF.
Conclusions: Evaluation of Bilharzial patients with thick periportal ﬁbrosis for pulmonary
hypertension is essential for detection and monitoring. Bilharziasis is considered an important cause
of mild pulmonary hypertension in developing countries.
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Schistosomiasis (Bilharziasis) [1] is the third-leading endemic
parasitic disease in the world, following malaria and amoebi-
asis. The disease ranks higher in prevalence than HIV/AIDS.
It is a major public health problem that is closely correlated
with socioeconomic conditions. The lung is a mandatory stepis. Production and hosting by Elsevier B.V. All rights reserved.
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306 M.Sh. Badawy et al.in the parasite life cycle. The parasite causes both acute and
chronic pulmonary lesions, depending on the cycle phase.
Pulmonary involvement should be suspected in patients with
even minor respiratory symptoms; it is more common than
previously suspected [2]. Chronic pulmonary disease is more
common in endemic areas and may present as asthma but,
more important, pulmonary vascular disease can result in
pulmonary hypertension and right heart failure (cor pulmo-
nale). The latter is one of the debilitating and fatal sequelae
of infection [3,4]. The majority of reported cases are due to
Schistosoma mansoni, with a few case reports due to Schisto-
soma hematobium [5] or Schistosoma japonicum [6]. The prev-
alence of pulmonary hypertension caused by schistosomal
infection is not known. Barbosa et al. [7] evaluated cardiopul-
monary involvement in 246 patients with suspected S. man-
soni infection living in an endemic area of Brazil. High
pulmonary artery pressure was found in 25% of subjects on
Doppler echocardiography; of these, 80% had schistosomiasis.
Other small studies in Brazil have reported pulmonary hyper-
tension in 7.5–21.6% of patients with schistosomiasis [8], schis-
tosomiasis is considered to be the major cause of pulmonary
hypertension worldwide; it may even be the leading cause of
pulmonary hypertension in endemic areas. However, the prev-
alence, clinical proﬁle, and pathology are still unknown.
Aim of the work
To evaluate presence of pulmonary hypertension in Bilharzial
patients and its clinical proﬁle.
Materials and methods
A case control study was conducted on patients with bilhar-
ziasis who were admitted to the Internal Medicine depart-
ment or out patient’s clinic at Qena University Hospital
from March 2012 to January 2013. Ninety subjects (80 males
and 10 females) were recruited; 50 were bilharzial and 40 as
control and both groups were matched for age and sex. Inclu-
sion criteria: all bilharzial patients had one or more of the
following criteria: previous history of anti-bilharzial therapy;
positive anti-bilharzial antibodies; positive rectal snip, and
Bilharzial hepatic peri-portal ﬁbrosis. Exclusion criteria: pa-
tients were excluded if they have any of the followings: pa-
tient with congenital pulmonary stenosis; patient with non
bilharzial liver cirrhosis; hepatic malignancy and portal vein
thrombosis; patient with advanced age, co-morbidity and
pregnant females; previous history of alcoholism; positive
serology for hepatitis B and C and HIV; previous history
of proven autoimmune disease; splenectomized patients; the
use of hepatotoxic drugs; refusing to participate in the study.
The study protocol was approved by the local ethics commit-
tee and all patients gave their consent prior to the study.
Schistosomal pulmonary and portal hypertension were estab-
lished on the basis of combination of clinical history, exami-
nation and investigations. Laboratory study includes: urine
analysis; stool analysis; and liver function tests: ALT, AST,
serum albumin, total bilirubin, prothrombin time, and con-
centration. Abdominal ultrasonography: liver size: classiﬁed
as shrunken (<11 cm), average (11–15 cm), or enlarged
(>15 cm) [9]. Presence of hepatic periportal ﬁbrosis was
seen[10]. Portal vein diameter and patency: The normal PVis up to 13 mm in diameter. It was measured from the inner
to the inner wall during suspended respiration [11,12]. Splenic
size: normally, it is up to 12–13 cm. If enlarged, it is classiﬁed
as mild (13–16 cm), moderate (16–20 cm), or huge (>20 cm)
splenomegaly [10,11]. Status of ascites: if present, it was re-
ported as either minimal ascites or moderate to severe ascites.
Criteria suggestive of portal hypertension by ultrasonography
are an increased diameter of the portal and splenic veins, the
presence of portosystemic collaterals, splenomegaly and asci-
tes [11].
Echocardiography: All patients underwent complete trans-
thoracic echocardiographic evaluation with Samsung Vivid 3
(China) with 3 MHz frequency probe. A 2.5 MHz phased ar-
ray transducer was used. Transthoracic M-Mode echocardiog-
raphy (TEE) was initially performed with the patient in the
supine position or on the left side [13]. All images were
obtained from parasternal long- and short-axis and apical
four-chamber view. The heart and its performance are also
commonly measured in terms of dimensions, which is much
easier to estimate with M-Mode echocardiography (Van
Dam et al. [13]). Right ventricular end-systolic diameter
(RVESD) and end-diastolic diameter (RVEDD) were evalu-
ated in apical four-chamber view. RV ejection fraction
(RVEF) is assumed to be a major determinant of systolic
RV function, and has been shown to be of prognostic value
in PH [14]. Tricuspid regurge: Pathologic regurgitation is often
due to right ventricular and tricuspid annular dilation second-
ary to pulmonary hypertension or RV dysfunction [15].
Secondary ﬁndings like right atrial and RV enlargement often
accompanied signiﬁcant chronic TR. Pulmonary artery diame-
ter: the normal diameter of main pulmonary artery is 0.9–
2.9 cm (corrected to height) and normal annulus diameter is
1–2.2 cm [16]. Pulmonary artery pressure: tricuspid regurgitant
velocity is derived from the application of continuous wave
doppler along the tricuspid regurgitant jet, from apical four
chamber projections. Right atrial (RA) pressure was estimated
according to the degree of inferior vena cava inspiratory col-
lapse. The pulmonary artery systolic and diastolic pressures
were then calculated. Pulmonary artery systolic pressure
(PASP) was considered elevated if it exceeded 30 mmHg [17].
The peak velocity reﬂects the RV to right atrial pressure differ-
ence, and in the absence of pulmonary stenosis, the RV systolic
pressure (RVSP) is assumed to equal pulmonary artery systolic
pressure (PASP), and is calculated through the Bernoulli equa-
tion: (Fisher et al. [18] PASP = RVSP = 4 (VTR)2 + RAP
Zoghbi et al. [19]) where VTR: tricuspid regurgitant velocity,
RAP: right atrial pressure. Pulmonary artery diastolic pres-
sure: the Bernoulli Equation can be applied to calculate pul-
monary arterial end-diastolic pressure (PEDP): PEDP = 4
(VED) 2 + RAP (Lo´pez-Candales et al. [20]) where VED:
end-diastolic pulmonary regurgitant velocity.Statistical analysis
Data entry and analysis were done using statistical package
of social science (SPSS) version 11. The data are presented
as means ± SD. Independent sample t test was done to com-
pare the results between groups and was used to assess the
signiﬁcance of comparing ﬁne and thick periportal ﬁbrosis
within the same group. The signiﬁcance was established at
P< 0.05.
Table 4 Laboratory data in patient subgroups.
Variables Fine (n= 40) Thick (n= 10) P value
ALT (U/L) 15.5 ± 5.4 ±5.216.01 NS
AST (U/L) 20.6 ± 5.2 25.4 ± 9.15 NS
T. bilirubin (mg/dl) 0.539 ± 0.001 0.65 ± 0.214 0.014
Albumin (g/dl) 4.20 ± 0.29 4.30 ± 0.47 NS
Prothrombin time (sec) 11.80 ± 0.68 13.9 ± 1.8 0.000
Prothrombin conc. (%) 92.92 ± 4.59 78.68 ± 11.42 0.000
Data are expressed as mean ± SD. Independent sample t test was
used in analysis.
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Group 1: They included 50 patients 44 males (88%) and six fe-
males (12%) with their mean age 34.24 ± 9.68 years. It was
classiﬁed according to the degree of periportal ﬁbrosis by
abdominal ultrasonography into subgroup (a) patients with
ﬁne PPF; they were 40 (80%), and subgroup (b) patients with
thick PPF, they were 10 (20%). Group 2: Normal subjects as
control group. They included 40 subjects, 36 males (90%)
and four females (10%) with their mean age 33.9 ± 9.23 years.
Patients and control were comparable in their demographic
data with no statistically signiﬁcant difference (Table 1).
In group 1, there was past history of bilharziasis with pre-
vious antibilharzial therapy in 26 patients (52%), history of
terminal hematuria in four patients (8%), and history of dys-
entery in eight patients (16%). Clinically, there were hepato-
megaly in 30 patients (60%) and splenomegaly in 40 patients
(80%) (Table 2).
Laboratory data: No statistically signiﬁcant difference was
found in liver function tests (total bilirubin, serum albumin, li-
ver enzymes (ALT and AST), prothrombin time and concen-
tration) between patients and control (Table 3).
In patient group, patients with thick PPF showed statisti-
cally signiﬁcant lower values in prothrombin concentration
(P value = 0.000) and statistically signiﬁcant higher values inTable 1 Demographic data of both groups (patient and
control).
Variable Patients (n= 50) Control (n= 40) P value
Age (ys) 34.24 ± 9.68 33.9 ± 9.23 NS
Male, n (%) 44 (88%) 36 (90%) NS
Female, n (%) 6 (12%) 4(10%)
Data are expressed as mean ± SD or as number (%). Chi2 test was
used in analysis.
Table 2 Clinical presentations of patient group.
Variables Patients (n= 50)
History of bilharziasis 26 (52%)
History of previous antibilharzial therapy 26 (52%)
History of terminal hematuria 4 (8%)
History of dysentery 8 (16%)
Hepatomegaly 30 (60%)
Splenomegaly 40 (80%)
Table 3 Laboratory data of both studied groups (patients and
control).
Variables Patients (n= 50) Control (n= 40) P value
ALT (U/L) 17.14 ± 10.4 17.6 ± 11.6 NS
AST (U/L) 21.6 ± 8.4 22.37 ± 9.2 NS
T. bilirubin (mg/dl) 0.562 ± 0.136 0.55 ± 0.130 NS
Albumin (g/dl) 4.22 ± 0.33 4.19 ± 0.32 NS
Prothrombin time (sec) 12.22 ± 1.3 12.02 ± 1.27 NS
Prothrombin conc. (%) 90.07 ± 8.59 92.27 ± 6.57 NS
Data are expressed as mean ± SD. Independent sample t test was
used in analysis.prothrombin time (P value = 0.000) and total bilirubin (P va-
lue = 0.014) than those with ﬁne PPF. No statistically signiﬁ-
cant differences were found in liver enzymes (ALT, AST) and
albumin between both patients’ subgroups (Table 4).
There were statistically signiﬁcant higher values in liver size
at midclavicular line (P value = 0.000) and in splenic size (P
value = 0.000) in patients than control and also in patients
with thick PPF than those with ﬁne PPF (Tables 5 and 6).
Echocardiographic data are summarized in (Table 7). Eight
of the 50 bilharzial patients studied had PASP >30 mmHg
(range, 30–38 mmHg) representing 16% of this group. Accord-
ing to echocardiographic parameters, we found statistically
signiﬁcant lower values in ejection fraction (EF) (P va-
lue = 0.016) and statistically signiﬁcant higher values in pul-
monary artery diameter (PAD) and pulmonary artery
pressure (P value = 0.000) in patients than control.
In the patient group, patients with thick PPF showed statis-
tically signiﬁcant lower values in ejection fraction (EF) and sta-
tistically signiﬁcant higher values of pulmonary artery pressure
(P value = 0.01) than those with ﬁne PPF but no statisticallyTable 5 The size of the liver and the spleen by abdominal
ultrasonography in both groups (patients and control).
Variables Patients (n= 50) Control (n= 40) P value
Liver span in MCL(cm) 11.878 ± 1.72 10.6 ± 0.86 0.000
Size of spleen(cm) 14.596 ± 3.45 8.28 ± 1.64 0.000
Table 6 The size of the liver and the spleen by abdominal
ultrasonography in patient subgroups.
P value Thick (n= 10) Fine (n= 40) Variables
0.003 13.30 ± 2.81 11.52 ± 1.12 Liver span in MCL(cm)
0.0001 16.60 ± 4.20 13.34 ± 2.14 Size of spleen(cm)
Table 7 Echocardiographic parameters of both groups
(patients and control).
P value Patients (n= 50) Control (n= 40) Variables
0.003 1.47 ± 0.43 1.22 ± 0.281 RVSD (cm)
0.0001 2.04 ± 0.41 1.687 ± 0.298 RVDD (cm)
0.009 59.14 ± 4.00 61.2 ± 3.18 EF%
0.0001 1.85 ± 0.34 1.55 ± 0.287 PAD (cm)
0.0001 26.72 ± 6.43 21.85 ± 2.63 PASP
0.0001 12.56 ± 2.33 10.47 ± 1.09 PADP
Table 8 Echocardiographic parameters in patient subgroups.
P value Fine (n= 40) Thick (n= 10) Variable
0.005 1.39 ± 0.34 1.81 ± 0.60 RVSD (cm)
0.007 1.967 ± 0.37 2.35 ± 0.41 RVDD (cm)
0.023 59.78 ± 3.58 56.6 ± 4.77 EF%
NS 1.82 ± 0.32 1.95 ± 0.40 PAD (cm)
0.000 25.7 ± 5.17 32.8 ± 7.6 PASP
0.014 12.1 ± 1.57 14.1 ± 3.57 PADP
RVSD: right ventricular systolic dimension; RVDD: right ventric-
ular diastolic dimension; EF: ejection fraction; PAD: pulmonary
artery diameter; PASP: pulmonary artery systolic pressure; PADP:
pulmonary artery diastolic pressure.
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diameter (PAD) between patient subgroups (Table 8).
Discussion
Qena governorate, in Upper Egypt, is located about 535–
650 km south of Cairo on the Nile River. The total rural target
population is 1,731,252. The prevalance of schistosomiases in
Qena was 12% in 1988 and it decreased to 1.4% in 2011
according to the recent report of MOH. The prevalence of
infection was slightly more in ezbas than in their mother vil-
lages. Prevalence and intensity of infection were higher at all
ages in males than in females [21].
Pulmonary hypertension represents one of the most severe
complications of chronic schistosomiasis particularly in its
hepatosplenic presentation but its occurrence in the absence of
hepatosplenomegaly has also been reported by De Cavalcanti
et al. [22]. Portal hypertension almost invariably precedes
PAH in schistosomiasis, establishing venous shunts between
the portal and systemic circulation, allowing the passage of
schistosome eggs from the liver to the lungs [23]. Portal hyper-
tension opens more collateral circulation, thus increasing
blood ﬂow to the lungs and enhances shear stress in pulmonary
vessels [24].
Our study showed 16% prevalence of elevated systolic pul-
monary artery pressure by echocardiography in patients with
the hepatosplenic form of schistosomiasis who live in endemic
area in Qena. Echocardiography still has a major role for the
indication of right heart catheterization, the gold standard
for diagnosis of pulmonary hypertension [25]. Out of the 50
bilharzial patients studied, 8 had mild pulmonary hyperten-
sion, PASP >30 mmHg (range, 30–38 mmHg) representing
16% of this group. In most textbooks available, the upper limit
of normal systolic pulmonary artery pressure (SPAP) is
30 mmHg [26]. This was consistent with Barbosa et al. [25],
Lapa et al. [27], and Mies et al. [28] who showed that patients
with Schistosomiasis mansoni and portal hypertension had mild
form of pulmonary hypertension.
The prevalence of PH varies with the type of the study (clin-
ical, echocardiographic, angiographic, or necropsy studies)
from 7% to 70%, although most studies using Doppler echo-
cardiographic data have shown an incidence between 20% and
30%.The study that reported a prevalence of 70% used a cut
off value of 15 mmHg for the mean pulmonary pressure, which
is very low, so probably normal patients were misclassiﬁed as
having PH [29]. A recent screening study has demonstrated a
4.6% prevalence of pulmonary hypertension in patients withhepato-splenic schistosomiasis. This low relative prevalence
said that, it is quite evident that not just the exposition to
the schistosoma egg is enough to induce PH in bilharzial pa-
tients but other factors may intervene in the PH genesis [25].
Right Ventricular ejection fraction (RVEF) is assumed to
be a major determinant of systolic RV function and has been
shown to be of prognostic value in PH [14]. According to echo-
cardiographic parameters, we found statistically signiﬁcant
lower values in RV ejection fraction (RVEF) and statistically
signiﬁcant higher values in pulmonary artery diameter
(PAD) and pulmonary artery pressure in patients than control.
The same results were reported by Farrag et al. [30] that pa-
tients with schistosomiasis had increased mean values of
LVEF, RV diameters, RA area, VC width and pulmonary ar-
tery pressures. On contrary, they had decreased mean values of
RVEF. Sir-Chen et al. [31] reported that dilated pulmonary ar-
tery, in particular of the right descending pulmonary artery, is
the consequence of elevated pulmonary artery pressure (PAP)
or increased blood ﬂow.
In patient subgroups, patients with thick PPF showed sta-
tistically signiﬁcant lower values in ejection fraction (EF)
and statistically signiﬁcant higher values of pulmonary artery
pressure than those with ﬁne PPF but no statistically signiﬁ-
cant differences could be detected in pulmonary artery diame-
ter (PAD) between patient subgroups. The current study had
some limitations. First, the study sample was relatively small.
We therefore acknowledge that this sample may not be repre-
sentative of the actual prevalence of schistosomiasis-related
pulmonary hypertension in the whole endemic areas in Egypt.
Second, invasive hemodynamic assessment to conﬁrm pulmon-
ary artery pressures was not performed.Conclusions
Evaluation of Bilharzial patients with thick periportal ﬁbrosis
for pulmonary hypertension is essential for detection and mon-
itoring. Bilharziasis considered an important cause of mild
pulmonary hypertension in developing countries and most of
cases remain undiagnosed.References
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